← All trials
NCT03424629
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2018
- Primary completion
- Sep 30, 2018
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tianjin Ever Union Biotechnology Co., Ltd.Lead sponsor
- Peking UniversityStudy chair
- Peking UniversityOverall official - principal investigator
- Peking UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.